StockNews.com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBGet Rating) in a report issued on Monday. The firm set a “sell” rating on the stock.

Shares of NAVB stock opened at $0.76 on Monday. The firm has a market cap of $23.04 million, a P/E ratio of -1.90 and a beta of 1.75. Navidea Biopharmaceuticals has a 52 week low of $0.72 and a 52 week high of $2.19. The stock’s 50 day moving average is $0.82.

Navidea Biopharmaceuticals Company Profile (Get Rating)

Navidea Biopharmaceuticals, Inc engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Featured Stories

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.